Nuvation Bio Files Preliminary Prospectus for $200M Convertible Senior Notes Offering
NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (2.2× avg).
Summary
Nuvation Bio is proposing a $200 million offering of convertible senior notes due 2032 to repay existing debt and for general corporate purposes, with capped call transactions intended to reduce future dilution.
Key Events · Financing and Capital Events · NUVB
-
Proposed $200 Million Convertible Senior Notes Offering
Nuvation Bio is offering $200 million in principal amount of Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $30 million.
-
Use of Proceeds
Net proceeds will be used to pay for capped call transactions, repay approximately $50 million in obligations under a senior secured loan agreement, and for general corporate purposes.
-
Convertible Nature and Dilution Mitigation
The notes are convertible into cash, Class A common stock, or a combination, at the company's election. Capped call transactions are expected to reduce potential dilution upon conversion.
-
Preliminary Terms
The preliminary prospectus supplement does not yet specify the interest rate or the initial conversion price per share, indicating final terms are pending.
Analysis · NUVB · Life Sciences
Nuvation Bio has filed a preliminary prospectus supplement for a proposed $200 million offering of convertible senior notes due 2032. This substantial capital raise, representing approximately 8.8% of the company's market capitalization, aims to strengthen the balance sheet. Proceeds will be used to repay $50 million in existing secured debt, which improves the company's debt structure, and for general corporate purposes. The notes are convertible into cash, Class A common stock, or a combination, at the company's election, with capped call transactions expected to mitigate potential dilution from stock conversion.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUVB was trading at $5.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.81 to $9.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.